SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

April 21, 2015 07:00 ET

Baltimore Sun Publishes Op-Ed by CTD Executive Chairman and Scientific Advisory Board Member

Insightful Op-Ed, "Building Local Capacity to Fight Epidemics," Says Training Local Medical Virologists Is the Most Effective Way to Combat Global Epidemics

ALACHUA, FL--(Marketwired - April 21, 2015) - CTD Holdings, Inc. (OTCQB: CTDH) Executive Chairman of the Board N. Scott Fine and Scientific Advisory Board Member Dr. Sharon H. Hrynkow have co-authored a highly insightful and thoughtful op-ed in The Baltimore Sun titled, "Building Local Capacity to Fight Epidemics," which states that the most effective way to stop viruses such as Ebola, MERS and Chikungunya from becoming global pandemics is to prevent them from spreading beyond their point of origin. To do so, local medical virologists in every country must receive training and support that allow them to develop and implement programs that contain and combat viruses.

Mr. Fine and Dr. Hrynkow's op-ed points to the successful containment of Ebola in Nigeria last year -- a miraculous feat in Africa's most populous country. The key to this response was a trained epidemiology and laboratory team already in place in Nigeria that was able to contain individual cases, preventing the virus from spreading throughout Nigeria and into other countries. Read the entire op-ed at http://www.baltimoresun.com/news/opinion/oped/bs-ed-gvn-20150420-story.html

Mr. Fine and Dr. Hrynkow are also Chairman of the Board and President, respectively, of the Global Virus Network (GVN), a coalition of the world's leading medical virologists in more than 25 countries. The op-ed's other distinguished co-authors are Dr. Robert C. Gallo, Founder and Scientific Director of GVN and Director of the Institute of Human Virology at the University of Maryland School of Medicine, a GVN Center of Excellence; and Dr. Diane E. Griffin, University Distinguished Professor, W. Harry Feinstone Department of Molecular Microbiology and Immunology, and Director of GVN Center of Excellence at Johns Hopkins Bloomberg School of Public Health.

About the Company: 
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: www.ctd-holdings.com and www.cyclodex.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information